Viking Therapeutics, Inc. (NASDAQ:VKTX) shares climbed in Wednesday’s extended trading after the company released its fourth-quarter earnings report.
Here’s a look at the key figures from the quarter.
- VKTX stock is moving. Watch the price action here.
The Details: Viking Therapeutics reported quarterly losses of $1.38 per share, which missed the analyst estimate for losses of 89 cents, according to data from Benzinga Pro.
Viking said the increase in net loss for the quarter was primarily due to increased research and development expenses.
Research and development expenses were $153.5 million for the fourth quarter, compared to $31 million for the same period in 2024.
The increase was primarily due to increased expenses related to clinical studies, stock-based compensation and salaries and benefits, partially offset by decreased expenses related to manufacturing for drug candidates and preclinical studies.
“The past year was an exceptional year for Viking, marked by rapid progress across our obesity portfolio,” stated Brian Lian, Ph.D., CEO of Viking.
VKTX Stock Price: According to data from Benzinga Pro, Viking Therapeutics stock rose 8.58% to $31 in Wednesday’s extended trading.
Photo: Shutterstock
Recent Comments